AGENDA

Uniform Formulary Beneficiary Advisory Panel (BAP)
For the August 2023 Department of Defense Pharmacy and Therapeutics Committee Meetings September 27, 2023 at 10:00 AM Eastern Daylight Saving Time

Virtual Meeting

➢ General session starts at 10:00 AM Eastern Daylight Saving Time
    (Administrative meeting preceding)

➢ Roll Call

➢ Therapeutic Class Reviews

Members of the Defense Health Agency (DHA) Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the Department of Defense (DoD) Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended complete exclusion candidates.

The DoD P&T Committee made recommendations for the following drugs/drug classes during the August 2023 meeting:

➢ Drug Class Reviews

- Luteinizing Hormone-Releasing Hormone (LHRH) Agonists-Antagonists – Prostate Cancer, Endometriosis and Fibroids, and Central Precocious Puberty subclasses
- White Blood Cell Stimulants – Filgrastims and Pegfilgrastims

➢ Newly Approved Drugs per 32 CFR 199.21(g)(5)

- atropine sulfate 1% ophthalmic solution – Ophthalmic Miscellaneous: Mydriatics
- deutetetabenazine extended-release tabs (Austedo XR) – Neurological Agents Miscellaneous: Movement Disorders
- fecal microbiota spores, live-brpk capsules (Vowst) – Gastrointestinal-2 Agents Miscellaneous
- fezolinetant (Veozah) – Gynecological Agents Miscellaneous
- leniolisib (Joenja) – Immunological Agents Miscellaneous
- omaveloxolone (Skyclarys) – Neurological Agents Miscellaneous
- perfluorohexylcoctane 1.338 g/mL ophthalmic solution (Miebo) – Ophthalmic: Dry Eye Agents
- sildenafil 10 mg/mL oral suspension (Liqrev) – Pulmonary Arterial
Hypertension (PAH): PDE 5 Inhibitor

- sodium oxybate extended-release packets for oral suspension (Lumryz) – Sleep Disorders: Wakefulness Promoting Agents
- somapacitan-beco injection (Sogroya) – Growth Stimulating Agents
- sotagliflozin (Inpefa) – Diabetes Non-Insulin: Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
- trientine tetrahydrochloride tablets (Cuvrior) – Binder-Chelators-Antidotes-Overdose
- zavegepant nasal spray (Zavzpret) – Migraine Agents
- zolpidem tartrate 7.5 mg capsules – Sleep Disorders: Insomnia

▶ Utilization Management Issues

- New Manual Prior Authorization (PA) Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)
  - Vitamins: Prenatal—Prenatal Multivitamin (Natal PNV)
- PA Criteria—Updated PA Criteria for New FDA-Approved Indications
  - Anticonvulsant and Anti-Mania: topiramate ER capsule sprinkle (Qudexy XR) and topiramate ER capsule (Trokendi XR)
  - Migraine Agents: CGRP Antagonists Oral Agents Subclass—atogepant (Qulipta)
  - Gastrointestinal-2 Agents: CIC/IBS-C—linaclotide (Linzess)
  - CGM: Therapeutic Continuous Glucose Monitoring Systems—Freestyle Libre 2 and 3
  - Atopy Agents: Oral Janus Kinase Inhibitor (JAK-1)—upadacitinib (Rinvoq)
  - Oncological Agents: Ovarian Cancer—olaparib (Lynparza)
  - Oncological Agents—dabrafenib (Tafinlar) and trametinib (Mekinist)
  - Oncological Agents—avapritinib (Ayvakit)
  - Targeted Immunomodulatory Biologics (TIBs)—sarilumab (Kevzara)
- PA Criteria—Updated PA Criteria for Reasons Other Than New Indications
  - Neurological Agents Miscellaneous—risdiplam (Evrysdi)
  - Hematological Agents—avacopan (Tavneos)
  - Targeted Immunomodulatory Biologics: Tumor Necrosis Factor
Inhibitors—adalimumab (Humira)

- Brand Over Generic PA Authorization and Tier 1 copay
  - dabigatran (Pradaxa) Capsules

- Completely Excluded Drugs: Annual Review

- Drugs Subject to Section 703 National Defense Authorization Act (NDAA) For Fiscal Year 2008
  - tidezolid (Sivextro)
  - lefamulin (Xenleta)

- Panel Discussions

  The BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoD P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.